Radiation-Induced Nausea and Vomiting (RINV) High Risk
ÎBased on extrapolation from indirect evidence, the Update Committee recommends that all patients should receive a 5-HT3
antagonist before
each fraction and for at least 24 hours after completion of radiotherapy. Patients should also receive a five-day course of dexamethasone during fractions 1-5.
Moderate Risk ÎThe Update Committee recommends that patients receive a 5-HT3 Low Risk ÎThe Update Committee recommends a 5-HT3 antagonist alone as either
prophylaxis or rescue. For patients who experience RINV while receiving rescue therapy only, prophylactic treatment should continue until radiotherapy is complete.
Minimal Risk
ÎPatients should receive rescue therapy with either a dopamine receptor antagonist or a 5-HT3
antagonist. Prophylactic antiemetics should
continue throughout radiation treatment if a patient experiences RINV while receiving rescue therapy.
Combined Chemotherapy and Radiation Therapy
ÎPatients should receive antiemetic prophylaxis according to the emetogenicity of chemotherapy, unless the emetic risk with the planned radiotherapy is higher.
antagonist
before each fraction for the entire course of radiotherapy. Patients may be offered a short course of dexamethasone during fractions 1-5.
